Ecallantide in acute hereditary angioedema

BioDrugs

Volumn 25, Issue 1, 2011, Pages 51-52

  Garnock Jones, Karly P ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Profile Reports; Ecallantide, general; Hereditary angioedema; Research and development

Indexed keywords

BRADYKININ; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; KALBITOR; KALLIKREIN; KININOGEN; PLACEBO; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ARTICLE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78651348155     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11206960-000000000-00000     Document Type: Article

References (11)

1. Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009 May; 102 (5): 366-72
2. Kaplan A, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol 2010 Mar; 104 (3): 193-204
3. Dyax Corp. Kalbitor® (ecallantide subcutaneous injection): US prescribing information [online]. Available from URL: http://www.kalbitor.com/ pdf/Kalbitor Full Prescribing Information.pdf [Accessed 2010 Mar 30]
4. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov 2010 Mar; 9 (3): 189-90
5. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Invest Drugs 2006 Sep; 15 (9): 1077-90
6. US FDA. Center for Drug Evaluation and Research application number 125277: ecallantide pharmacology review part 1 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/125277s000Pharm R-P1.pdf [Accessed 2010 Apr 12]
7. Garnock-Jones KP. Ecallantide: in acute hereditary angioedema. Drugs 2010; 70 (11): 1423-31
8. Levy RJ, Lumry WR, Mc Neil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010 Jun; 104 (6): 523-9
9. Levy R, Mc Neil D, Li H, et al. Results of a phase 3 double-blind, placebocontrolled trial, EDEMA3®: a study of subcutaneous DX-88 (ecallantide) in patients with hereditary angioedema [abstract no. 15]. Ann Allergy Asthma Immunol 2008 Jan; 100 (1 Suppl. 1): A6
10. Levy R, Mc Neil D, Li H, et al. Results of a 2-stage, phase 3 pivotal trial, EDEMA3®: a study of subcutaneous DX-88 (ecallantide), a plasma kallikrein inhibitor, in patients with hereditary angioedema [abstract no. 398-A]. J Allergy Clin Immunol 2008 Feb; 121 (2 Suppl. 2A): S103
11. sm: a study of subcutaneous ecallantide in patients with hereditary angioedema [abstract no. 1081]. J Allergy Clin Immunol 2007 Jan; 119 (1 Suppl.): S276